Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

Abstract

Apilimod was well-tolerated but did not demonstrate efficacy over placebo in patients with active CD.